Hyperion Revealed As Andromeda’s Mystery Buyer In $570M Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The California biotech is adding to its orphan drug roster with the purchase of the Israeli biotech and its late-stage type 1 diabetes treatment in a back-loaded deal that leaves little room for risk.